Mimicking Borderline Resectable Population in Solitary Hepatocellular Carcinoma of BCLC Stage A

Background Early recurrence (≤ 6 months) after curative resection of hepatocellular carcinoma (HCC) carries markedly worse prognosis than late recurrence. While borderline resectable (BR1/BR2) HCC is defined anatomically, a biologically high-risk subgroup with BR-like features may exist within resectable (R) disease; we developed and validated a preoperative score to identify such patients within BCLC Stage A primary HCC. Methods We analyzed a single-center discovery cohort of 473 patients with solitary BCLC Stage A primary HCC (2001–2021) and a later validation cohort of 63 patients (2022–2025). An additive 2-factor score (0–2) combined tumor size (≥ 60 mm) and PIVKA-II (≥ 50 mAU/mL); ROC/Youden-index analysis in the same cohort yielded closely similar thresholds. Bootstrap resampling that re-derived cutoffs within each replicate showed a less optimistic, more variable AUC than the fixed-cutoff model. Results Early recurrence occurred in 44/473 (9.3%) discovery patients and carried worse 5-year overall survival than late or no recurrence (38.1% vs. 78.4% vs. 94.6%; p < 0.001). Tumor size ≥ 60 mm (OR 3.94) and PIVKA-II ≥ 50 mAU/mL (OR 2.27) were independent predictors. The score stratified early-recurrence risk in discovery (score 0/1/2: 4.4%/7.7%/27.9%; AUC 0.694, optimism-corrected 0.662–0.692) and validation cohorts (5.6%/12.2%/50.0%; AUC 0.664, 95% CI 0.421–0.870), and was independently associated with distant recurrence after adjustment for early-recurrence status (adjusted OR 3.01 per point, p < 0.001). Conclusions A simple 2-factor score combining tumor size and PIVKA-II identifies, within solitary BCLC Stage A HCC, a high-risk subgroup whose recurrence mimics borderline resectable (BR1) disease. Preoperative (neoadjuvant) systemic therapy in this high-risk group warrants prospective evaluation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11544562/v1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Mimicking Borderline Resectable Population in Solitary Hepatocellular Carcinoma of BCLC Stage A

Yuki Ushimaru, Yoshihiro Sakano, Yuki Yokota, Shogo Kobayashi et al.
Research Square
Hepatocellular Carcinoma Treatment and Prognosis
preprint

Mimicking Borderline Resectable Population in Solitary Hepatocellular Carcinoma of BCLC Stage A

Yuki Ushimaru, Yoshihiro Sakano, Yuki Yokota, Shogo Kobayashi, Yoshinori Kagawa, Hiroshi Miyata, Yoshitomo Yanagimoto, Kazuyoshi Yamamoto, Takashi Kanemura, Hisateru Komatsu, Yasunari Fukuda, Toshinori Sueda, Masatoshi Kitakaze, Norihiro Matsuura, Tsuyoshi Hata, Kunihito Gotoh, Kei Adachi, Kota Momose, Kaoru Fujikawa, Yuta Kobayashi, Kei Yamamoto
preprint en

Abstract

Background Early recurrence (≤ 6 months) after curative resection of hepatocellular carcinoma (HCC) carries markedly worse prognosis than late recurrence. While borderline resectable (BR1/BR2) HCC is defined anatomically, a biologically high-risk subgroup with BR-like features may exist within resectable (R) disease; we developed and validated a preoperative score to identify such patients within BCLC Stage A primary HCC. Methods We analyzed a single-center discovery cohort of 473 patients with solitary BCLC Stage A primary HCC (2001–2021) and a later validation cohort of 63 patients (2022–2025). An additive 2-factor score (0–2) combined tumor size (≥ 60 mm) and PIVKA-II (≥ 50 mAU/mL); ROC/Youden-index analysis in the same cohort yielded closely similar thresholds. Bootstrap resampling that re-derived cutoffs within each replicate showed a less optimistic, more variable AUC than the fixed-cutoff model. Results Early recurrence occurred in 44/473 (9.3%) discovery patients and carried worse 5-year overall survival than late or no recurrence (38.1% vs. 78.4% vs. 94.6%; p < 0.001). Tumor size ≥ 60 mm (OR 3.94) and PIVKA-II ≥ 50 mAU/mL (OR 2.27) were independent predictors. The score stratified early-recurrence risk in discovery (score 0/1/2: 4.4%/7.7%/27.9%; AUC 0.694, optimism-corrected 0.662–0.692) and validation cohorts (5.6%/12.2%/50.0%; AUC 0.664, 95% CI 0.421–0.870), and was independently associated with distant recurrence after adjustment for early-recurrence status (adjusted OR 3.01 per point, p < 0.001). Conclusions A simple 2-factor score combining tumor size and PIVKA-II identifies, within solitary BCLC Stage A HCC, a high-risk subgroup whose recurrence mimics borderline resectable (BR1) disease. Preoperative (neoadjuvant) systemic therapy in this high-risk group warrants prospective evaluation.

Research Square
Osaka International Cancer Institute (JP)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon